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Resumen 
La resistencia a la combinación de ß-lactámico/inhibidor de ß-lactamasa en enterobacterias es un 
problema creciente que no ha sido estudiado intensamente en Argentina. En el presente trabajo, 54/843 
enterobacterias recolectadas en un hospital universitario de la ciudad de Buenos Aires fueron resistentes 
a ampicilina-sulbactama, pero se mantuvieron sensibles a las cefalosporinas de segunda y tercera 
generación. Se analizaron los mecanismos enzimáticos presentes en los aislamientos que también 
fueron resistentes a amoxicilina-ácido clavulánico (AMC) (18/54). La secuenciación reveló dos variantes 
diferentes de blaTEM-1, donde blaTEM-1b es el alelo más frecuentemente detectado (10 Escherichia coli, 3 
Klebsiella pneumoniae, 2 Proteus mirabilis y 1 Raoultella terrigena), seguidos por blaTEM-1a (1 K. 
pneumoniae). La resistencia a AMC parece estar asociada principalmente con la hiperproducción de 
TEM-1 (sobre todo en E. coli) o con la coexpresión con ß-lactamasas tipo OXA-2 y/o SHV (K. 
pneumoniae y P. mirabilis). Se describió una nueva variante de blaTEM (TEM-163) en un aislamiento de E. 
coli que presentó una CIM frente a AMC de 16/8 µg/ml. La enzima TEM-163 contiene dos sustituciones 
de aminoácidos respecto de TEM-1, Arg275Gln y His289Leu. Teniendo en cuenta la alta actividad 
específica observada y la baja IC50 para el ácido clavulánico, el patrón de resistencia de este 
aislamiento parece obedecer a la hiperproducción de la nueva variante de la ß-lactamasa de amplio 
espectro, en lugar de vincularse con un comportamiento similar al de una TEM resistente a inhibidores 
(IRT). 
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Abstract 
Resistance to ß-lactam/ß-lactamase inhibitors in enterobacteria is a growing problem that has not been 
intensively studied in Argentina. In the present work, 54/843 enterobacteria collected in a teaching 
hospital of Buenos Aires city were ampicillin-sulbactam-resistant isolates remaining susceptible to 
second-and third-generation cephalosporins. The enzymatic mechanisms present in the isolates, which 
were also amoxicillin-clavulanic acid (AMC)-resistant (18/54) were herein analyzed. Sequencing revealed 
two different variants of blaTEM-1, being blaTEM-1b the most frequently detected allelle (10 Escherichia 
coli, 3 Klebsiella pneumoniae, 2 Proteus mirabilis and 1 Raoultella terrigena) followed by blaTEM-1a (1 K. 
pneumoniae). Amoxicillin-clavulanate resistance seems to be mainly associated with TEM-1 
overproduction (mostly in E. coli) or co-expressed with OXA-2-like and/or SHV ß-lactamases (K. 
pneumoniae and P. mirabilis). A new blaTEM variant (TEM-163) was described in an E. coli strain having 
an AMC MIC value of 16/8 µg/ml. TEM-163 contains Arg275Gln and His289Leu amino acid substitutions. 
On the basis of the high specific activity and low IC50 for clavulanic acid observed, the resistance pattern 
seems to be due to overproduction of the new variant of broad spectrumß-lactamase rather than to an 
inhibitor-resistant TEM (IRT)-like behavior. 
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Introduction  
Amoxicillin-clavulanate (AMC) is one of the most frequently prescribed antibiotic 
combinations in many countries, especially in ambulatory patients. For this reason, even 
if it is still a low occurrence event, resistance to ß-lactam/ ß-lactamase inhibitors among 
enterobacteria clinical isolates is an emerging worldwide problem. Different enzymatic 
mechanisms are associated with AMC resistance: hyperproduction of chromosome-
encoded class C ß-lactamases, acquired plasmid-encoded cephalosporinases (AmpC 
type), hyperproduction of plasmid-mediated class A ß-lactamases (such as TEM-1 and 
SHV-1 enzymes), production of class D oxacillinases and inhibitor-resistant TEM (IRTs 
or CMTs) and SHV mutants6,14,19,23 (whose ß-lactamase activities are poorly inhibited by 
clavulanate). In addition to enzymatic mechanisms, a decrease in the expression or 
absence of outer membrane proteins might also be involved, i.e., a deficiency in the 
OmpF and/or OmpC production has been associated to this phenotype in Escherichia 
coli4. 
IRTs were frequently described as plasmid-encoded enzymes derived from TEM-1 or 
TEM-2 ß-lactamases and detected mainly from European isolates. Substitutions of one 
or more amino-acid residues at positions 69, 244, 275 and 276 render structural 
changes in ß-lactamases that affect affinity for inhibitors, but produce only slight 
modifications in the isoelectric point (pI) or activity on other ß-lactam compounds. Other 
substitutions also found in IRT ß-lactamases do not seem to be involved in the IRT 
phenotype9. 
Overproduction of both TEM-1 and SHV-1, or production of an IRT may increase 
resistance to amoxycillin, ticarcillin, amoxicillin-clavulanic acid and, frequently to 
piperacillin and ticarcillin-clavulanic acid, while only slightly affecting susceptibility to 
narrow spectrum cephalosporins, cephamycins, extended-spectrum cephalosporins, 
and, in most cases, to piperacillin-tazobactam3. 
Over the last years, an increase in the rate of resistance to AMC has been noted among 
E. coli isolates in our country. According to the "Sistema Informático de Resistencia 
(SIR)" susceptibility to ampicillin-sulbactam in E. coli has been decreasing from 62%22 
(years 2004-2005) to 50% (years 2006-2008; M. Radice, personal communication). In 
spite of the high use of this association, there is little information available about the 
prevalence of AMC resistance mechanisms in Enterobacteriaceae. 
The aim of this study was to investigate the enzymatic mechanisms of amoxicillin-
clavulanate-resistant entero-bacteria lacking inducible chromosomal ampC genes 
isolated from a teaching hospital of Buenos Aires city. 
Materials and methods  
Microorganisms  
Isolates recovered from different clinical specimens that fulfilled a screening criteria 
(Enterobacteriaceae resistant to ampicillin-sulbactam but remaining susceptible to 
cefoxitin, ceftazidime and cefotaxime by a disk diffusion method) were studied. Isolates 
were collected within a 5-month period (May to September 2008) from patients 
attending the Hospital de Clínicas that belongs to UBA (University of Buenos Aires) 
"José de San Martín", Buenos Aires, Argentina. 
E. coli ATCC 35218, TEM-1 basal level producer, was used as reference. 
Susceptibility testing  
Antimicrobial susceptibility testing was performed using the disk diffusion method and 
the agar dilution method as described by the Clinical Laboratory Standard Institute 
(CLSI). Results were interpreted accordin g to the CLSI guidelines2. Tested antibiotics 
were ampicillin (AMP), ampicillin-sulbactam (AMS), Amoxicillin-clavulanic acid (AMC), 
piperacillin (PIP), piperacillin/tazobactam (PTZ), cephalothin (CTN), cefoxitin (FOX), 
ceftriaxone (CRO), ceftazidime (CAZ), cefepime (FEP), imipenem (IMP), meropenem 
(MER), ertapenem (ERT), amikacin (AMI), gentamicin (GEN), polymyxin B (POL), 
trimethoprim-sulfamethoxazole (TMS), ciprofloxacin (CIP), nitrofurantoin (NIT). AMS 
and AMC MICs were tested at a 2:1 fixed ratio. Antimicrobial agents tested and reported 
were obtained from Britania S.A. (disks) and Klonal laboratorios (drugs), Argentina. 
ß-lactamase assays  
Cells were harvested by centrifugation from overnight LB broth cultures and 
resuspended in 0.5 ml of sodium phosphate buffer (0.1 M, pH 7). ß-lactamases were 
released by sonication (ten 1-min high-frequency discontinuous bursts on ice at output 
4-5 and duty cycle: 50%) using SonicVibra Cell ultrasonic processor (Sonics & Materials 
Inc., USA). 
Isoelectric focusing was performed with crude extracts applied to polyacrylamide gels 
(pH gradient 3-10) in an LKB 2117-Multiphor II isoelectric focusing tank (LKB Produkter 
AB, Sweden), as previously described15. ß-Lactamase activity was revealed by the agar 
iodometric system using AMP (500 mg/l) as substrate, as previously described25. TEM-1 
(pI 5.4), SHV-2 (pI 7.6), OXA-2 (pI 7.7) and CTX-M-2 (pI 8.2) producing strains were 
used as standards and were run simultaneously with the samples. 
Semi-quantification of ß-lactamase production was determined as described below: total 
protein concentration in crude enzyme preparations was determined by the Bradford 
method (Bio-Rad Laboratories, USA), adjusted at the same protein concentration and 
diluted with 100 mM sodium phosphate buffer (pH 7.0). ß-Lactamase activity of each 
enzymatic extract and decimal dilutions (20 µl) were evaluated using the iodometric 
method employing AMP as substrate. Clinical isolates that showed ß-lactamase activity 
in dilutions higher than the reference strain were considered enzyme overproducers. 
Specific activity was determined in those isolates harboring ß-lactamases that focused 
at pI 5.4. This activity was measured three times per strain by the spectrophotometric 
assay using nitrocefin (482 nm) as substrate at a final concentration of 100 µM. TEM-1 
overproduction was arbitrarily defined when specific activity was at least two-fold higher 
than E. coli ATCC 35218. 
Inhibition studies were performed by measuring the residual ß-lactamase activity of 
crude extracts previously pre-incubated with clavulanic acid (0.1, 1 and 10 µM) for 15 
min at room temperature. IC50 was defined as the clavulanic acid concentration required 
to inhibit 50% of the ß-lactamase activity. 
Detection of blaTEM, blaSHV and blaOXA genes  
Molecular detection of blaTEM, blaSHV and blaOXA-1, blaOXA-2 and blaOXA-10 group was 
carried out by PCR amplification using specific primers (Table 1). The reaction mixture 
contained 2 µl of total heat extracted DNA as template, and 1.25 U of T-free DNA 
polymerase (Inbio Highway, Argentina) was added to a total volume of 50 µl containing 
0.2 mM deoxynucleoside triphosphate, 20 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2, 50 mM 
KCl, and 0.5 µM primers. The reaction protocol required an initial step of 5 min at 95°C, 
followed by 30 cycles of 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min, with a final 
extension at 72°C for 20 min. E. coli ATCC 35218, K. pneumoniae ATCC 700603, 
Salmonella Infantis S215 and Enterobacter cloacae 15321 strains were used as positive 
controls. 
 
Sequencing of the blaTEM genes  
PCR products were purified using either the GFXTM PCR DNA or Gel Band Purification 
Kit (Amersham Biosciences, Piscataway, NJ, USA). blaTEM sequences were performed 
on an ABI 377 DNA sequencer (Perkin Elmer, Applied Biosystems). The nucleotide 
sequences and their derived amino acid sequences were compared to previously 
described sequences obtained from the GenBank database and ß-lactamase 
classification in Lahey website (http://www.lahey.org/Studies/), respectively. Sequences 
were aligned using Vector NTI Suite 9 program (InforMax, Inc.). 
Molecular epidemiology  
The genetic relationship between the-AMC-resistant E. coli isolates was determined by 
REP-PCR. 
Nucleotide accession numbers  
The nucleotide sequence of a novel variant of blaTEM gene (blaTEM-163) was deposited in 
the GenBank database under accession number EU815939. 
Results  
Susceptibility testing  
Fifty-four (6.4%) out of a total of 843 documented infections were caused by different 
Enterobacteriaceae that fulfilled the proposed selection criterion. These bacteria, 
lacking inducible chromosomal AmpC genes, were: 38 E. coli, 8 K. pneumonia, 5 P. 
mirabilis, 2 K. oxytoca and 1 Raoultella terrigena, and displayed MIC values of AMS 
higher than 16/8 µg/ml. 
As not all AMS-resistant isolates are also AMC-resistant16,18; therefore, AMC 
susceptibility was first determined by the agar disk diffusion method. Taking this feature 
into account, 18/54 (33.3%) isolates were finally selected to characterize the ß-
lactamase/s involved: 7 of them were clearly AMC-resistant with inhibition zone 
diameters <14 mm (2 E. coli, 1 R. terrigena, 2 K. pneumoniae and 2 P. mirabilis), 8 had 
intermediate susceptibility (all E. coli, with inhibition zone diameters between 14-17 mm) 
and 3 had border line susceptibility (1 E. coli and 2 K. pneumoniae, inhibition zone = 18 
mm). 
Resistance profiles were further explored by MIC determination to a large set of 
antibiotics. Relevant results are shown in Table 2. All of them were sensitive to FOX but 
PIP and CTN susceptibility was variable. All isolates remained susceptible to PTZ, 
extended-spectrum cephalosporins (CRO, CAZ, FEP) and carbapenems (IMP, MER, 
ERT) tested (data not shown). Thus, chromosomal or plasmid AmpC hyper-producing 
and CMT-producing isolates were ruled out. 
 
Regarding susceptibility to non ß-lactam antibiotics, 9/ 11 E. coli were resistant to TMS, 
4/11 to CIP and 3/11 to NIT; 4/4 K. pneumoniae were resistant to TMS and NIT, 2/4 
were resistant or had intermediate susceptibility to GEN and AMK, and 1/4 was 
resistant to CIP; and finally 2/2 P. mirabilis were resistant to GEN and NIT, and 1/2 was 
resistant to CIP. Except for natural resistance in P. mirabilis, all isolates were 
susceptible to POL. 
Resistance mechanisms  
All crude extracts showed ß-lactamase activity when analyzed by the iodometric assay 
employing AMP as substrate. Characterization of the ß-lactamases revealed that all 
extracts possessed, at least, an enzyme that focused at pI 5.4 and 7/18 co-produced 
other enzymes that focused at different pI (Table 3). Ten of eleven E. coli isolates only 
displayed the pI 5.4 enzyme. 
All isolates were positive for blaTEM and PCR products were sequenced subsequently. 
Variants of the blaTEM-1 gene were detected, being blaTEM-1b described in 16 isolates. 
The blaTEM-1a allele was only noted in one K. pneumoniae strain (Table 3) and no 
other variants of blaTEM-1 gene were detected. An E. coli isolate (strain 3343) produced a 
new variant of the blaTEM gene (named blaTEM-163), which differed from blaTEM-1b in 3 bp 
(see below for more details). 
 
When tested for other ß-lactamase genes by PCR, only one E. coli, three K. 
pneumoniae and two P. mirabilis isolates were positive for blaOXA-2-group genes (Table 
3). The blaSHV gene was only detected in all K. pneumoniae isolates. Not a single isolate 
rendered a positive amplification for blaOXA-1 or blaOXA-10 group. These results agreed 
with pI values previously obtained. 
Most isolates that only harbored the blaTEM-1 determinant (7 E. coli and 1 R. terrigena) 
showed a higher level of TEM-1 production, and could be considered as probable TEM-
1 overproducers since they showed an enzyme production 2-12-fold higher than E. coli 
ATCC 35218 (Table 3). The remaining two E. coli strains, with intermediate 
susceptibility to AMC, displayed a basal or slightly increased level of TEM-1, suggesting 
that other mechanisms would be involved in the susceptibility decrease observed. 
Results achieved by the spectrophotometer method were coincident with those obtained 
by the iodometric semi-quantitative assay. 
E. coli 3343, in which the new TEM-163 was present, also showed a profile compatible 
with TEM overproduction (with a specific activity that was 6-fold higher than E. coli 
ATCC 35218). In this case, IC50 values for clavulanic acid were similar to t he IC50value 
measured on the reference TEM-1-producing strain (IC50 around of 1µM). Because of 
these characteristics, rather than thinking of TEM-163 as a probable IRT ß-lactamase, 
the AMC-resistance phenotype is likely due to overproduction of this new ß-lactamase. 
As expected from isolates that were mostly obtained from urine samples with no strong 
epidemiological link, even those producing only a TEM ß-lactamase, the different E. coli 
isolates are assumed as the different clones displayed a dissimilar banding profile by 
REP-PCR (data not shown). 
TEM-163 versus TEM-122  
TEM-163-producing E. coli was resistant to AMP, AMS (MIC≥32/16 µg/ml), PIP and 
CTN, of intermediate susceptibility to AMC (MIC=16/8 µg/ml) and susceptible to FOX 
(Table 2). The blaTEM-163 gene presents more than 99% identity with blaTEM-122 
(previously considered IRT)10. blaTEM-122 variant (accession number AY307100) could be 
considered a blaTEM-1b-derived gene that has a G→A transition at base 812, leading to 
Arg→Gln amino acid change at position 275 (numbering according to Ambler et al.1). A 
new mutation (A→T transversion) at base 854 was detected in blaTEM-163 producing a 
His→Leu amino acid substitution at position 289 in the mature protein of TEM-163, 
which has not been previously reported (Table 4). Distinctiveness of these mutations 
was verified by sequencing both the coding and non-coding strands from two 
independent PCR reactions. 
 
Discussion  
We have focused the study on ß-lactamases present in different Enterobacteriaceae 
with phenotypic resistance toß-lactam/ß-lactamase inhibitors but remaining susceptible 
to cefoxitin and extended-spectrum cephalosporins. During the 5-month period of our 
study the overall frequency of ampicillin-sulbactam-resistant isolates (all non-inducible 
AmpC producing enterobacteria) remained at about 6.4%. Among them, we selected 
those that also showed a reduced inhibition zone to AMC by the disk diffusion test to 
describe the enzymatic mechanisms that are poorly known in our country. AMC 
resistance in Enterobacteriaceae is a complex phenomenon with heterogeneous clinical 
implications. 
The overproduction of TEM-like enzymes followed by TEM-1 production in combination 
with OXA-2-type and/or SHV-type ß-lactamases were the main mechanisms identified. 
In agreement with literature data, genes encoding TEM-1 were detected in the majority 
of the isolates examined, being blaTEM-1b the predominant allelic variant (16/18) 
identified so far, and only one blaTEM-1a harboring strain (K. pneumonia 3400) was 
described. Consistently, other blaTEM-1 variants (i.e. blaTEM-1c, blaTEM-1d, blaTEM-1e), rarely 
detected in enterobacteria13,17, were not found. 
The presumed overproduction of TEM-1 ß-lactamase in E. coli, which was present in 
7/11 isolates with reduced susceptibility to AMC, was the main mechanism responsible 
for that resistance profile. These data are similar to those detected in E. coli by Pérez-
Moreno et al. in Spain20, although other researchers have observed a lower 
proportion19,24. 
At least two mechanisms may lead to TEM overproduction: 1- multiple copies of the 
blaTEM gene due to the presence of multiple copies of a plasmid per cell have been 
reported to cause overproduction of ß-lactamase or, 2- different promoter regions have 
been widely reported in various isolates. Even though blaTEM-1a and blaTEM-1b alleles 
were initially associated with a weak promoter7 (called P3), it is known that stronger 
promoters could be present (i.e., Pa/ Pb, P4, P5) upstream of blaTEM-like genes, which 
would explain the higher levels of production of TEM enzymes11-13. 
Two E. coli isolates producing a basal or slightly increased level of TEM-1 as a single 
resistance mechanism showed reduced susceptibility to AMC and CTN, being the 
reduced permeability or increased efflux to ß-lactam antibiotics the possible resistance 
mechanisms involved4,20. 
In the present study, OXA-2-type enzymes were mainly associated with K. pneumoniae 
and P. mirabilis, while the OXA-1 and OXA-10 groups were not detected. OXA-2-like 
enzymes, known to be more poorly inhibited by clavulanic acid than class A ß-
lactamases, accounted for 33% (6/18) of the isolates analyzed, but when E. coli 
determinants were compared with other studies13,19,20,24, the frequency of OXA-
producing E. coli remained low (1/11). 
Genes encoding SHV-1 and other close related enzymes have been shown to be 
natural in K. pneumoniae chromosome9; therefore blaSHV detection in this species is 
always expectable. 
Contribution of IRT ß-lactamases to AMC resistance in Enterobacteriaceae appear to 
be different in isolates from diverse countries. In this study, IRT-like enzymes were not 
detected among isolates having intermediate susceptibility and also among those that 
were clearly resistant. To the best of our knowledge, the presence of IRT-producing 
isolates appears to be much less common in the American continent than in Europe14. 
Nevertheless, amplification and direct sequencing of blaTEM has contributed to discover 
a new enzymatic variant called TEM-163 present in an E. coli strain having intermediate 
susceptibility to AMC (MIC= 16/8 mg/l). The predicted amino acid sequence of the latter 
contained the same substitution present in TEM-12210 (Arg275Gln), and also provided an 
extra mutation (His289Leu), which has not been previously described. 
An in silico model of TEM coevolution network and its communities was constructed by 
Guthrie et al., and the two mutant positions described in this work (275, 289) are 
included within the inhibitor-resistant ß-lactamase community. Interestingly, position 289 
is located at the interface between the two communities8 (extended-spectrum and 
inhibitor resistance). 
The amino acid substitution at position 275 (located at the C-terminal of the a-11 helix) 
was previously considered important to confer resistance to ß-lactamase inhibitors. 
However, the same substitution (Arg275Gln) was involved in TEM-45 (IRT-14), TEM-82 
and TEM-83 but these enzymes contained at least a second mutation in residue 6910,13, 
which was highly associated with IRT enzymes3,9. 
The absence of a mutation in residue 69 on this newß-lactamase in agreement with its 
low IC50 to clavulanic acid allow us to speculate that TEM-163 is more clearly a new 
variant of broad spectrum ß-lactamase than an IRT enzyme (IC50>10 µM is considered 
a probable IRT enzyme20). In conclusion, amoxicillin-clavulanate resistance in different 
species of non-inducible AmpC Enterobacteriaceae isolated in a teaching hospital from 
Buenos Aires seems to be mainly associated with TEM-1 overproduction or TEM-1, 
OXA-2-like and/or SHV-like ß-lactamase co-production. 
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